L3VLUP
ProSign in

PCRX in the 13F filings

Pacira Biosciences Inc · CUSIP 695127100

Sector · Pharmaceuticals and biotechnologyTheme · Healthcare: biopharma and medtech· L3VLUP-definedTheme · Pharmaceutical preparations
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Quarter end
30 Jun 2024
the date the book describes
Filed
14 Aug 2024
latest of these filings; the earliest 25 Jul 2024
Managers listing it
4
at least, of 95 tracked, among listed positions
Comparable managers
94
filed both Q1 2024 and Q2 2024; 3 listed it in both
Shares listed
3,938,703
combined, among listed positions
Reported value
$113m
combined, at the quarter end

Among the 94 comparable managers: 3 buyers (opened or added shares) and 1 seller (trimmed or exited), at least, among listed positions. Their net change in shares was +244,380.

Managers listing PCRX in Q2 2024

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q1 2024, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

4 of 4 holders

ActionFiling
Renaissance Technologies LLC2,066,197$59m0.10%Added+184,0009 Aug 2024 (the filing on sec.gov)
Marshall Wace LLP971,143$28munder 0.1%Added+159,79114 Aug 2024 (the filing on sec.gov)
Baillie Gifford & Co806,097$23munder 0.1%Trimmed-194,67725 Jul 2024 (the filing on sec.gov)
Winton Group Ltd95,266$2.7m0.18%Newnew9 Aug 2024 (the filing on sec.gov)

Largest increases and reductions, by shares

Q1 2024 to Q2 2024, among managers that listed it in both quarters or opened it.

Increases

Reductions

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (1)

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
4 in Q3 2024 to 3 in Q2 2026

Tracked managers listing it, at least.

0358102014201620182020202220242026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
PCRX by quarter
QuarterHoldersReported valueBuyersSellers
Q2 20133$232mn.a.n.a.
Q3 20133$325mn.a.n.a.
Q4 20132$349mn.a.n.a.
Q1 20143$399mn.a.n.a.
Q2 20143$525mn.a.n.a.
Q3 20148$891mn.a.n.a.
Q4 20146$510mn.a.n.a.
Q1 20153$396mn.a.n.a.
Q2 20154$357mn.a.n.a.
Q3 20157$180mn.a.n.a.
Q4 20155$659mn.a.n.a.
Q1 20165$344mn.a.n.a.
Q2 20166$194mn.a.n.a.
Q3 20164$62mn.a.n.a.
Q4 20162$41mn.a.n.a.
Q1 20173$33mn.a.n.a.
Q2 20175$71mn.a.n.a.
Q3 20172$53mn.a.n.a.
Q4 20175$64mn.a.n.a.
Q1 20186$37mn.a.n.a.
Q2 20183$23mn.a.n.a.
Q3 20187$133mn.a.n.a.
Q4 20189$143mn.a.n.a.
Q1 20198$152mn.a.n.a.
Q2 20199$234mn.a.n.a.
Q3 201910$130mn.a.n.a.
Q4 20197$228mn.a.n.a.
Q1 20209$190mn.a.n.a.
Q2 20208$307mn.a.n.a.
Q3 20205$344mn.a.n.a.
Q4 20205$335mn.a.n.a.
Q1 20214$313mn.a.n.a.
Q2 20216$303mn.a.n.a.
Q3 20216$251mn.a.n.a.
Q4 20216$269mn.a.n.a.
Q1 20226$332mn.a.n.a.
Q2 20225$239mn.a.n.a.
Q3 20225$206mn.a.n.a.
Q4 20225$144mn.a.n.a.
Q1 20236$174mn.a.n.a.
Q2 20238$174mn.a.n.a.
Q3 20235$111mn.a.n.a.
Q4 20235$102m32
Q1 20243$108m22
Q2 20244$113m31
Q3 20244$41m32
Q4 20244$68m32
Q1 20257$178m61
Q2 20255$117m32
Q3 20254$109m04
Q4 20255$57m1711
Q1 20263$45m620
Q2 20263$49m1413

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

PCRX and LLY →PCRX and JNJ →PCRX and VRTX →Choose a stock to compare with PCRX →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own PCRX, latest filings →Back to the 13F Explorer →